A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 42,514 shares of GILD stock, worth $3.88 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
42,514
Previous 972,163 95.63%
Holding current value
$3.88 Million
Previous $66.7 Million 94.66%
% of portfolio
0.02%
Previous 0.3%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$66.59 - $83.99 $61.9 Million - $78.1 Million
-929,649 Reduced 95.63%
42,514 $3.56 Million
Q2 2024

Aug 09, 2024

BUY
$63.15 - $72.88 $12.4 Million - $14.3 Million
196,672 Added 25.36%
972,163 $66.7 Million
Q1 2024

May 09, 2024

BUY
$71.58 - $87.29 $49.4 Million - $60.2 Million
689,570 Added 802.56%
775,491 $56.8 Million
Q4 2023

Feb 09, 2024

BUY
$73.27 - $83.09 $2.85 Million - $3.23 Million
38,837 Added 82.48%
85,921 $6.96 Million
Q3 2023

Nov 13, 2023

BUY
$73.94 - $80.67 $1.44 Million - $1.57 Million
19,436 Added 70.3%
47,084 $3.53 Million
Q2 2023

Aug 10, 2023

SELL
$76.01 - $86.7 $11.7 Million - $13.3 Million
-153,844 Reduced 84.77%
27,648 $2.13 Million
Q1 2023

May 09, 2023

BUY
$77.31 - $88.08 $10.5 Million - $12 Million
135,982 Added 298.8%
181,492 $15.1 Million
Q4 2022

Feb 10, 2023

BUY
$62.32 - $89.47 $259,625 - $372,732
4,166 Added 10.08%
45,510 $3.91 Million
Q3 2022

Nov 10, 2022

BUY
$59.54 - $68.01 $765,029 - $873,860
12,849 Added 45.09%
41,344 $2.55 Million
Q2 2022

Aug 05, 2022

SELL
$57.72 - $65.01 $19.4 Million - $21.8 Million
-335,610 Reduced 92.17%
28,495 $1.76 Million
Q1 2022

May 12, 2022

BUY
$57.92 - $72.58 $12.6 Million - $15.8 Million
217,083 Added 147.65%
364,105 $21.6 Million
Q4 2021

Feb 10, 2022

BUY
$64.88 - $73.64 $5.2 Million - $5.9 Million
80,182 Added 119.96%
147,022 $10.7 Million
Q3 2021

Nov 12, 2021

SELL
$67.69 - $73.03 $468,144 - $505,075
-6,916 Reduced 9.38%
66,840 $4.67 Million
Q2 2021

Aug 12, 2021

BUY
$63.47 - $69.35 $340,833 - $372,409
5,370 Added 7.85%
73,756 $5.08 Million
Q1 2021

May 13, 2021

SELL
$60.0 - $68.46 $888,780 - $1.01 Million
-14,813 Reduced 17.8%
68,386 $4.42 Million
Q4 2020

Feb 16, 2021

BUY
$56.65 - $64.55 $2.01 Million - $2.29 Million
35,480 Added 74.35%
83,199 $4.85 Million
Q3 2020

Nov 12, 2020

SELL
$62.1 - $78.08 $1.9 Million - $2.39 Million
-30,553 Reduced 39.03%
47,719 $3.02 Million
Q2 2020

Aug 13, 2020

BUY
$72.34 - $84.0 $1.66 Million - $1.93 Million
23,010 Added 41.64%
78,272 $6.02 Million
Q1 2020

May 13, 2020

SELL
$62.63 - $80.22 $218,891 - $280,368
-3,495 Reduced 5.95%
55,262 $4.13 Million
Q4 2019

Feb 12, 2020

BUY
$61.62 - $67.78 $107,835 - $118,615
1,750 Added 3.07%
58,757 $3.82 Million
Q3 2019

Nov 13, 2019

SELL
$62.51 - $69.0 $956,403 - $1.06 Million
-15,300 Reduced 21.16%
57,007 $3.61 Million
Q2 2019

Aug 07, 2019

SELL
$61.87 - $69.38 $1.98 Million - $2.22 Million
-31,950 Reduced 30.65%
72,307 $4.89 Million
Q1 2019

May 08, 2019

BUY
$62.53 - $70.05 $2.79 Million - $3.13 Million
44,625 Added 74.83%
104,257 $6.78 Million
Q4 2018

Feb 12, 2019

SELL
$60.54 - $79.0 $2.71 Million - $3.53 Million
-44,743 Reduced 42.87%
59,632 $3.73 Million
Q3 2018

Nov 13, 2018

BUY
$71.28 - $78.92 $2.79 Million - $3.08 Million
39,075 Added 59.84%
104,375 $8.06 Million
Q2 2018

Aug 02, 2018

SELL
$64.88 - $75.68 $22,708 - $26,488
-350 Reduced 0.53%
65,300 $4.63 Million
Q1 2018

May 14, 2018

SELL
$72.84 - $88.8 $7.31 Million - $8.91 Million
-100,383 Reduced 60.46%
65,650 $4.95 Million
Q4 2017

Feb 09, 2018

BUY
$71.15 - $83.52 $1.16 Million - $1.36 Million
16,258 Added 10.85%
166,033 $11.9 Million
Q3 2017

Nov 14, 2017

SELL
$72.11 - $85.47 $4.55 Million - $5.4 Million
-63,150 Reduced 29.66%
149,775 $12.1 Million
Q2 2017

Aug 14, 2017

BUY
N/A
212,925
212,925 $15.1 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $114B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Connor, Clark & Lunn Investment Management Ltd. Portfolio

Follow Connor, Clark & Lunn Investment Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.